Greenwich LifeSciences (GLSI) News Today $12.39 -0.13 (-1.04%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Greenwich LifeSciences Partners With Breast C...November 26, 2024 | benzinga.comGreenwich LifeSciences Partners with GIM in ItalyNovember 26, 2024 | globenewswire.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Buys $12,910.00 in StockNovember 26, 2024 | insidertrades.comJaye Thompson Acquires 1,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson purchased 1,000 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $12.91 per share, for a total transaction of $12,910.00. Following the completion of the acquisition, the vice president now directly owns 264,148 shares in the company, valued at $3,410,150.68. The trade was a 0.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.November 25, 2024 | marketbeat.comGreenwich LifeSciences Provides Update on Corporate EventsNovember 18, 2024 | globenewswire.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 1.6% - Time to Sell?Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 1.6% - Should You Sell?November 14, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1% - Still a Buy?Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1% - Still a Buy?October 23, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 1,500 Shares of StockOctober 1, 2024 | insidertrades.comSnehal Patel Acquires 1,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 1,500 shares of the firm's stock in a transaction on Thursday, September 26th. The stock was acquired at an average price of $14.63 per share, for a total transaction of $21,945.00. Following the completion of the transaction, the chief executive officer now directly owns 5,536,102 shares of the company's stock, valued at approximately $80,993,172.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.September 30, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 800 SharesSeptember 17, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recentlySeptember 12, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$3.36m On Greenwich LifeSciencesAugust 17, 2024 | uk.finance.yahoo.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $72,490.00 in StockAugust 8, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 5,500 SharesGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 5,500 shares of the stock in a transaction on Monday, August 5th. The shares were acquired at an average cost of $13.18 per share, with a total value of $72,490.00. Following the acquisition, the chief executive officer now directly owns 5,532,602 shares in the company, valued at approximately $72,919,694.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.August 7, 2024 | marketbeat.comJaye Thompson Purchases 1,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockAugust 6, 2024 | insidertrades.comGreenwich Lifesciences Inc (GLSI)August 4, 2024 | investing.comGreenwich LifeSciences Provides Update on Expansion of Flamingo-01 into SpainAugust 1, 2024 | globenewswire.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $23,835.00 in StockJuly 25, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $23,835.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 1,500 shares of the business's stock in a transaction that occurred on Tuesday, July 23rd. The shares were purchased at an average price of $15.89 per share, for a total transaction of $23,835.00. Following the completion of the acquisition, the chief executive officer now owns 5,527,102 shares of the company's stock, valued at approximately $87,825,650.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.July 24, 2024 | marketbeat.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Acquires 1,000 Shares of StockJuly 23, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 1,000 SharesGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson purchased 1,000 shares of the company's stock in a transaction that occurred on Thursday, July 18th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $16,000.00. Following the completion of the transaction, the vice president now directly owns 261,348 shares of the company's stock, valued at approximately $4,181,568. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.July 22, 2024 | marketbeat.comGreenwich LifeSciences Set to Join Russell 2000 Index AgainJune 26, 2024 | globenewswire.comSnehal Patel Acquires 174,825 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockJune 18, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $2,499,997.50 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 174,825 shares of Greenwich LifeSciences stock in a transaction dated Thursday, June 13th. The stock was bought at an average price of $14.30 per share, for a total transaction of $2,499,997.50. Following the completion of the purchase, the chief executive officer now owns 5,525,602 shares of the company's stock, valued at approximately $79,016,108.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.June 17, 2024 | marketbeat.comGreenwich LifeSciences Announces $2.5 Million Private PlacementJune 14, 2024 | globenewswire.comGreenwich LifeSciences, Inc. (GLSI)May 26, 2024 | finance.yahoo.comHC Wainwright Brokers Lift Earnings Estimates for Greenwich LifeSciences, Inc. (NASDAQ:GLSI)Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Greenwich LifeSciences in a report issued on Wednesday, May 22nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnMay 24, 2024 | marketbeat.comGreenwich LifeSciences, Inc. Expected to Earn Q1 2025 Earnings of ($0.17) Per Share (NASDAQ:GLSI)Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Greenwich LifeSciences in a research note issued to investors on Wednesday, May 22nd. HC Wainwright analyst Y. Chen forecasts thatMay 23, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research report on Wednesday.May 22, 2024 | marketbeat.comGLSI Stock Earnings: Greenwich LifeSciences Beats EPS for Q1 2024May 20, 2024 | investorplace.comGLSI Stock Earnings: Greenwich LifeSciences Misses EPS for Q4 2023April 15, 2024 | markets.businessinsider.comSnehal Patel Buys 3,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockApril 4, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $57,240.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 3,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were acquired at an average cost of $19.08 per share, with a total value of $57,240.00. Following the completion of the transaction, the chief executive officer now directly owns 5,350,777 shares in the company, valued at approximately $102,092,825.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.April 3, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,500 SharesMarch 27, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $49,950.00 in StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 2,500 shares of the stock in a transaction on Friday, March 22nd. The stock was acquired at an average price of $19.98 per share, with a total value of $49,950.00. Following the completion of the acquisition, the chief executive officer now owns 5,347,777 shares of the company's stock, valued at approximately $106,848,584.46. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.March 26, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,500 SharesMarch 23, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,100 SharesMarch 16, 2024 | insidertrades.comGreenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025March 13, 2024 | globenewswire.comGreenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in EuropeMarch 12, 2024 | globenewswire.comGreenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional SharesMarch 7, 2024 | finance.yahoo.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 4,100 Shares of StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,100 shares of the business's stock in a transaction that occurred on Monday, March 4th. The shares were purchased at an average price of $13.03 per share, with a total value of $53,423.00. Following the completion of the acquisition, the chief executive officer now owns 5,340,277 shares of the company's stock, valued at approximately $69,583,809.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 6, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) Forecasted to Post Q1 2024 Earnings of ($0.20) Per ShareGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Greenwich LifeSciences in a note issued to investors on Wednesday, February 28th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.2March 2, 2024 | marketbeat.comExpanding Horizons: Bullish Buy Rating as Greenwich LifeSciences’s Breast Cancer Trial Goes Pan-EuropeanFebruary 28, 2024 | markets.businessinsider.comGreenwich LifeSciences stock jumps 8% on Phase 3 study expansionFebruary 27, 2024 | msn.comGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 27, 2024 | finanznachrichten.deGreenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European CountriesFebruary 27, 2024 | globenewswire.comGreenwich LifeSciences Stock (NASDAQ:GLSI) Dividends: History, Yield and DatesFebruary 23, 2024 | benzinga.comGreenwich LifeSciences, Inc.: Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European RegulatorsFebruary 22, 2024 | finanznachrichten.deGreenwich Lifesciences announces acceptance for Flamingo-01 trial by EMAFebruary 22, 2024 | msn.com Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now GLSI Media Mentions By Week GLSI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLSI News Sentiment▼0.000.59▲Average Medical News Sentiment GLSI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLSI Articles This Week▼01▲GLSI Articles Average Week Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OCS News Today ABUS News Today TRDA News Today PRTA News Today STOK News Today CAPR News Today ALT News Today MBX News Today PHAR News Today MLYS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLSI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.